ReviewBritish journal of cancer2022
Advances in the curative management of oesophageal cancer.
Review in British journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 4 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Advanced imaging (narrow band and acetic acid chromoendoscopy) and guided biopsies in surveillance of Barrett's oesophagus: a systematic review.BMJ open gastroenterology · 2026Pooled it
- Pooled it
- Systematic mapping of registered interventional studies addressing the top 10 research priorities in Barrett's oesophagus and gastro-oesophageal reflux disease.BMJ open gastroenterology · 2025Pooled it
- Germacrone: A Multi-targeting Sesquiterpene with Promising Anti-cancer and Chronic Disease Applications.Anti-cancer agents in medicinal chemistry · 2024Pooled it
- Symptomatic reactive hypoglycemia is highly prevalent post-esophagectomy.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2026Article
- Survival and Pathologic Response After Neoadjuvant Treatment in Esophagogastric Cancer: A Systematic Review.Diagnostics (Basel, Switzerland) · 2026Review
- Beyond Pathological Complete Response: Long-term Outcomes in Esophageal and Esophagogastric Junction Adenocarcinoma After Multimodal Therapy-A Systematic Review and Individual Patient-Data Meta-Analysis.Annals of surgical oncology · 2026Article
- Article
- The Geriatric Nutritional Risk Index and pulmonary function predict non-esophageal cancer-related mortality after esophagectomy.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Predictors and Patterns of Recurrence After a Watchful Waiting Approach following Clinical Complete Response to Neoadjuvant Radiochemotherapy for Esophageal Cancer.Current oncology (Toronto, Ont.) · 2026Article
- GPA33 forms a distinct diagnostic target class to Claudin 18.2 in oesophageal adenocarcinoma enabling the development of a novel GPA33 antibody-based detection platform.Cellular & molecular biology letters · 2026Article
- Development of a diagnostic model for esophageal achalasia assessed by esophageal high-resolution manometry using artificial intelligence.Experimental and therapeutic medicine · 2026Article
- Esophageal Cancer Cells Exhibit Heterogeneity in DNA Double-Strand Break Repair and G2/M Checkpoint Arrest Associated With Cell Viability After Ionizing Radiation.Advances in radiation oncology · 2026Article
- Spatial clustering of esophageal cancer in central Oromia, Ethiopia: A spatial autocorrelation and scan statistics analysis.PloS one · 2026Article
- Automated tumor regression grade assessment and survival prediction in esophageal cancer via weakly supervised multiple instance learning.Frontiers in medicine · 2026Article
- Article
- LAsting Symptoms after Oesophageal Resectional Surgery (LASORS): multicentre validation cohort study.The British journal of surgery · 2025Article
- The Current State of Robot-Assisted Minimally Invasive Esophagectomy (RAMIE): Outcomes from the Upper GI International Robotic Association (UGIRA) Esophageal Registry.Annals of surgical oncology · 2025Article
- A new NCL-targeting aptamer-drug conjugate as a promising therapy against esophageal cancer.Journal of nanobiotechnology · 2025Article
- Cell death mechanisms induced by gold nano-immunoconjugates-mediated photodynamic therapy against human oesophageal cancer stem cells.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of oesophageal cancer, in particular adenocarcinoma, has markedly increased over the last four decades with adenocarcinoma becoming the dominant subtype in the West, and mortality rates are high. Nevertheless, overall survival of patients with oesophageal cancer has doubled in the past 20 years, with earlier diagnosis and improved treatments benefiting those patients who can be treated with curative intent. Advances in endotherapy, surgical approaches, and multimodal and other combination therapies have been reported. New vistas have emerged in targeted therapies and immunotherapy, informed by new knowledge in genomics and molecular biology, which present opportunities for personalised cancer therapy and novel clinical trials. This review focuses exclusively on the curative intent treatment pathway, and highlights emerging advances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.